Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $18.00 target price on the stock. D. Boral Capital’s price target would suggest a potential upside of 187.77% from the stock’s current price.

Separately, Chardan Capital reiterated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, March 20th.

Coya Therapeutics Trading Up 9.5 %

Shares of NASDAQ:COYA traded up $0.55 during mid-day trading on Tuesday, reaching $6.26. The stock had a trading volume of 10,811 shares, compared to its average volume of 71,750. Coya Therapeutics has a 1 year low of $4.65 and a 1 year high of $10.24. The business’s 50 day moving average price is $6.20 and its 200 day moving average price is $6.42. The company has a market cap of $104.61 million, a P/E ratio of -9.67 and a beta of 0.49.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.14. The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million. Analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its holdings in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after buying an additional 4,777 shares during the period. XTX Topco Ltd purchased a new stake in shares of Coya Therapeutics during the 4th quarter worth $59,000. Jane Street Group LLC bought a new position in Coya Therapeutics in the fourth quarter worth about $74,000. Northern Trust Corp lifted its position in shares of Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after buying an additional 3,099 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Coya Therapeutics in the 4th quarter valued at about $401,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.